Année
2024
Auteurs
PUYOU DE POUVOURVILLE Gérard, Choquet Sylvain, Marchal Clarisse, Deygas Floriane, Deslandes Marine, Macher Nahid, Levy Vincent
Abstract
Ibrutinib is a Bruton’s tyrosine kinase inhibitor indicated for the first-line treatment and relapse of chronic lymphocytic leukaemia (CLL), Waldenström’s macroglobulinemia (WM) and mantle cell lymphoma (MCL). This study aimed to describe the characteristics of CLL patients treated with ibrutinib and its effectiveness, safety, and treatment pattern in real life.
CHOQUET, S., MARCHAL, C., DEYGAS, F., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G. et LEVY, V. (2024). A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS). Annals of Hematology, 103(8), pp. 2969-2981.